Bristol Myers Squibb adjusts its growth profile as FTSE Russell reshapes indexes. Dividend and earnings timeline support BMY stock story

By Thomas Clarke, Operations & Strategy desk. Reviewed on June 30, 2026 at 2:39 p.m. ET.

Bristol Myers Squibb (ISIN US0897961004) is seeing a shift in how its shares are categorized in major factor indexes after FTSE Russell removed the stock from several Russell growth benchmarks while keeping it in the broader Russell 3000 universe and the S&P 500. According to a detailed index update from IT BOLTWISE, the pharmaceutical group remains a large-cap constituent on the NYSE under the ticker BMY, while a confirmed quarterly dividend helps stabilize sentiment ahead of the next earnings report.

FTSE Russell reshapes growth exposure

The annual reconstitution by FTSE Russell has removed Bristol Myers Squibb from multiple growth-oriented benchmarks, including the Russell Top 200 Growth, Russell 3000 Growth and Russell 3000E Growth indexes, while leaving its inclusion in the broader Russell 3000 intact. The change is described in a companion report as an adjustment to the company's factor scoring rather than a signal of operational weakness, meaning that Bristol Myers Squibb continues to be treated as a large-cap healthcare name for broad US equity strategies.

The same reporting notes that Bristol Myers Squibb's large-cap status is underlined by a market capitalization in the region of roughly $116 billion, with the shares classified as a clear large cap despite the factor tilt away from growth. In trading following the rebalancing, the stock was last cited around $57.52 at the close, a level that represented a gain of nearly four percent versus the previous session and reflected some repositioning by factor-driven portfolios during the index changes. Because the company remains a member of the S&P 500, US benchmark investors continue to hold BMY as part of standard index exposure even as specialized growth strategies rebalance away from the name.

Dividend, earnings date and analyst context

The FTSE Russell move comes as Bristol Myers Squibb underscores its shareholder-return profile, with the company confirming a quarterly dividend of $0.63 per share payable on August 3, 2026 to investors of record on July 2, 2026. That confirmation is highlighted in the same index reconstitution coverage, which frames the payout as a supporting factor for sentiment during the period of factor reclassification and rebalancing.

On the earnings side, Bristol Myers Squibb has set July 30, 2026 as the date for its second-quarter report, with consensus expectations pointing to an earnings per share figure of $1.61, up about 10.3 percent from the prior-year quarter. A recent analysis from Zacks notes that the same report is projected to show quarterly net sales of $11.67 billion, representing an estimated 4.9 percent decline from the year-ago period. For the full year 2026, the Zacks consensus calls for earnings of $6.32 per share and revenue of $47.39 billion, changes of roughly +2.8 percent and -1.7 percent respectively versus the previous year.

The Zacks commentary also highlights that Bristol Myers Squibb's stock recently advanced 1.81 percent to close at $58.56 in a session where that performance outpaced the S&P 500's 1.18 percent gain. This outperformance, combined with upward revisions to fiscal 2026 earnings estimates by multiple analysts in the past 60 days, is cited as a reason the stock has been discussed in the context of momentum metrics, even as the FTSE Russell reclassification moves BMY out of official growth labels in several index families. For investors, the combination of a confirmed dividend, a near-term earnings event and evolving factor scores creates a nuanced backdrop for evaluating the shares' role in portfolios.

Camzyos and cardiovascular portfolio

Beyond index positioning and near-term numbers, Bristol Myers Squibb's product portfolio remains a central driver of its long-term investment case. In cardiovascular medicine, Camzyos, the company's therapy for obstructive hypertrophic cardiomyopathy, has been cited in coverage as a pipeline and regulatory focal point, including references to a priority-review option in the United States. In the same context, IT BOLTWISE points to ongoing regulatory steps linked to Camzyos as part of the background to Bristol Myers Squibb's changing factor profile, suggesting that the company's operational story continues to be informed by specialty-drug development even as index methodologies evolve.

Cardiovascular offerings complement Bristol Myers Squibb's established presence in immunology and oncology, where major therapies such as Opdivo and Eliquis have historically contributed a substantial share of revenue. A broader strategic discussion summarized by Intellectia.ai notes that Bristol Myers Squibb had ten products each generating more than $1 billion in annual sales in the recent past, underscoring the breadth of its commercial base. At the same time, that summary flags the patent-cliff risk around key therapies such as Eliquis and Opdivo, which are expected to lose market exclusivity in 2028, a change that could materially affect revenue trajectories later in the decade.

BMY stock and current pricing

Recent market-data snapshots put Bristol Myers Squibb's share price around the high-$50 range, with portals such as TradingKey citing a current price near $58.55 at a close on June 29, 2026, and a market capitalization of roughly $119.6 billion. The same data source reports a trailing twelve-month price-to-earnings ratio of about 16.4 and an earnings-per-share figure of approximately $3.47, giving a snapshot of how the market is valuing Bristol Myers Squibb's earnings stream at present.

As of June 30, 2026, 3:59 p.m. ET, a separate data compilation on MarketBeat lists Bristol Myers Squibb's last regular-session close at $58.46, with modest after-hours fluctuations around that mark. The site also notes that the stock recently gained around 1.63 percent in a single session, placing it in line with broader gains across US equity benchmarks and underscoring its role as a traded S&P 500 constituent in the healthcare sector.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.